BOCH
INZY

Blue Owl Capital Holdings’s Inozyme Pharma INZY Stock Holding History

Blue Owl Capital Holdings’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,080,027
Closed -$983K – 75
2025
Q1 		$983K Hold
1,080,027
– – 0.32% 35
2024
Q4 		$2.99M Sell
1,080,027
-40,000
-4% -$152K 0.69% 29
2024
Q3 		$5.86M Hold
1,120,027
– – 1.13% 22
2024
Q2 		$5M Sell
1,120,027
-150,000
-12% -$727K 1.39% 21
2024
Q1 		$9.73M Hold
1,270,027
– – 1.94% 14
2023
Q4 		$5.41M Buy
+1,270,027
New +$4.51M 1.29% 18

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Blue Owl Capital Holdings's INZY Position: Q2 2025 in Review

Blue Owl Capital Holdings sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 1,080,027 shares — an estimated $983K sold.

Blue Owl Capital Holdings first reported a position in INZY in Q4 2023 and held it in 6 quarters. The position peaked at $9.73M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Blue Owl Capital Holdings reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 1,080,027 Inozyme Pharma shares in Q2 2025, an estimated $983K.
  • Blue Owl Capital Holdings first reported a position in Inozyme Pharma in Q4 2023 and held it in 6 quarters.
  • Blue Owl Capital Holdings's Inozyme Pharma position peaked at $9.73M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2025, filed 11 Aug 2025.